Fig. 2: InflaMix-assigned clustering reproducibly associates with increased risk of disease progression or death across independent cohorts.
From: An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
a–i, Kaplan-Meier survival estimates of PFS and OS and rates of CR by day 100 by InflaMix clustering across all three validation cohorts. Odds ratios of no CR by day 100 and HRs estimated with 95% CI using regression models adjusted for age, primary refractory disease, costimulatory domain and prelymphodepletion LDH elevated above ULN. Estimates for PFS (a), OS (b) and rates of CR by day 100 (c) in the MSK cohort (Cohort II); and PFS (d), OS (e) and rates of CR by day 100 (f) in the SMC + HMH LBCL cohort (Cohort III). Estimates for PFS (g), OS (h) and rates of CR by day 100 (i) in the MCL and FL cohort (Cohort IV). Regression models used for Cohort IV adjusted for age, primary refractory disease, lymphoma subtype (MCL versus FL), and prelymphodepletion LDH elevated above ULN. Significance of cluster associations with clinical outcomes was determined by the Wald test. All tests were two sided with a significance level of 0.05. HMH, John Theurer Cancer Center of Hackensack Meridian Health.
